Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 908491
                    [Title] => Tolvaptan effective for hyponatremia for patients with heart failure — trials
                    [Summary] => 
Tolvaptan, a new vasopressin V2-receptor antagonist and the first and only oral drug in its class, has been shown in clinical trials to be an effective treatment for hypervolemic and euvolemic hyponatremia, especially for patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

                    [DatePublished] => 2013-02-14 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 887879
                    [Title] => Otsuka Philippines celebrates 15th year
                    [Summary] => 
Otsuka Philippines, one of the leading Japanese pharmaceutical companies in the Philippines, celebrated its 15th anniversary celebration last Dec. 4 at the Marriott Hotel.

                    [DatePublished] => 2012-12-20 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => http://imageshack.us/a/img338/6591/scitec4newthumb.jpg
                )

            [2] => Array
                (
                    [ArticleID] => 404112
                    [Title] => Effort on to promote liver wellness
                    [Summary] => In response to the alarming situation of chronic liver disease in the country, Otsuka (Philippines) Pharmaceutical Inc. ...
                    [DatePublished] => 2008-10-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

OTSUKA PHILIPPINES

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 908491
                    [Title] => Tolvaptan effective for hyponatremia for patients with heart failure — trials
                    [Summary] => 
Tolvaptan, a new vasopressin V2-receptor antagonist and the first and only oral drug in its class, has been shown in clinical trials to be an effective treatment for hypervolemic and euvolemic hyponatremia, especially for patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

                    [DatePublished] => 2013-02-14 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 887879
                    [Title] => Otsuka Philippines celebrates 15th year
                    [Summary] => 
Otsuka Philippines, one of the leading Japanese pharmaceutical companies in the Philippines, celebrated its 15th anniversary celebration last Dec. 4 at the Marriott Hotel.

                    [DatePublished] => 2012-12-20 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => http://imageshack.us/a/img338/6591/scitec4newthumb.jpg
                )

            [2] => Array
                (
                    [ArticleID] => 404112
                    [Title] => Effort on to promote liver wellness
                    [Summary] => In response to the alarming situation of chronic liver disease in the country, Otsuka (Philippines) Pharmaceutical Inc. ...
                    [DatePublished] => 2008-10-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Tolvaptan effective for hyponatremia for patients with heart failure — trials

February 14, 2013 - 12:00am

Tolvaptan, a new vasopressin V2-receptor antagonist and the first and only oral drug in its class, has been shown in clinical trials to be an effective treatment for hypervolemic and euvolemic hyponatremia, especially...

Science and Environment

Otsuka Philippines celebrates 15th year

December 20, 2012 - 12:00am

Otsuka Philippines, one of the leading Japanese pharmaceutical companies in the Philippines, celebrated its 15th anniversary...

Science and Environment

Effort on to promote liver wellness

October 2, 2008 - 12:00am

In response to the alarming situation of chronic liver disease in the country, Otsuka (Philippines) Pharmaceutical Inc. ...

Science and Environment